Content available at: https://www.ipinnovative.com/open-access-journals

Indian Journal of Pharmacy and Pharmacology

Journal homepage: https://www.ijpp.org.in/

Editorial

Application of artificial intelligence in drug development and patient care: An editorial overview

Soumyashree Tripathy[1], **Surya Kanta Swain***[2], **Bikash Ranjan Jena**[1]

[1]School of Pharmacy and Life Sciences, Centurion University of Technology and Management, Jatani, Odisha, India
[2]Amity Institute of Pharmacy, Amity University, Kolkata, West Bengal, India

Received: 25-08-2025; **Accepted:** 12-09-2025; **Available Online:** 25-09-2025

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

In recent years, there has been a significant increase in the digitization of data within the pharmaceutical industry. The digitization has rendered the learning, analysis, and application of intricate clinical situations vital. Artificial intelligence is employed to enhance the automation of extensive data management.[1] The extensive and complex process of drug development entails discovering possible pharmaceutical options for the treatment of various diseases. Artificial intelligence has revolutionized the drug discovery process. Artificial intelligence has revolutionized the pharmaceutical sector by expediting drug discovery, enhancing precision, and reducing costs.[1]

To accelerate and prevent drug discovery pipeline failures, AI approachess might be utilized to examine clinical report generated by public health authorities, individual health or pathology reports, and large molecular analysis.[2] An artificial intelligence system is a technological system that simulates human intellect utilize sophisticated tools and networks. This does not imply, however, that technology will ever completely take the place of people's actual presence.[3] Artificial intelligence (AI) uses systems and software that can evaluate and learn from the input data to accomplish certain objectives. Its applications in the pharmaceutical industry are continually growing.[4] AI has the ability to completeely revolutionary medication development process by improving its accuracy, proficiency, rapidity.[5] However, the successful use of AI requires the accessibility of reliable report, the resolution of social issues, with an understanding of the constraints of artificial intelligence-based methods.[6]

Recent research has significantly focused on AI applications in pharmaceutical chemistry, aiming to transform the pharmaceutical business.[7] The discovery and development of new pharmaceuticals is a protracted and arduous endeavor that employs labor-intensive techniques such as high-throughput screening and empirical testing. AI-driven techniques have been employed to forecast the potential adverse effects of drugs. These and other research endeavors have illustrated how AI might enhance the efficacy and efficiency of drug development processes.

2. Some Major Function of AI in Health Care and Patient Monitoring

One of AI and ML's main contributions to pharmaceutical development is their capacity for large scale data analysis at a speed that has never been achievable previously.[8] In the era of big data, scientists are constantly exposed to data from omics fields including genomics, proteomics, and metabolomics.[8] AI algorithms may be used to sort this sea of data in order to recognize patterns, correlations, and candidate biomarker for illness. Scientists are better equipped

*Corresponding author: Surya Kanta Swain
Email: swain_suryakant@yahoo.co.in

https://doi.org/10.18231/j.ijpp.64004.1758776264
© 2025 The Author(s), Published by Innovative Publications.

to decide which molecules to prioritize and which targets to pursue thanks to this data-driven method.[9] Additionally, researchers may expedite the initial stages of pharmaceutical development since AI-powered algorithms or programming with Python are excellent at predicting the biological activity of molecules.[10] Without requiring a lot of laboratory testing, these technologies can find viable drug candidates through virtual screening and predictive modeling. This not only speeds up the process of finding possible treatments, but it also drastically lowers the related expenses.[11] Authors illustrate AI applications throughout the drug development pipeline, including computationally demanding de novo design and likely property prediction algorithms. In relation to open-source databases and AI-based software tools that aid in drug development, the issues of molecular representation, information gathering, convolution, and differences among labels are examined.[12] It also examines how contemporary AI methods (such as graph neural networks, reinforcement learning, and generated models) and structure-based methods (such as molecular docking and molecular dynamics simulations) may support drug development, application, and evaluation. Lastly, new breakthroughs and expenditures on AI-based startups for medication creation, biotechnology, and their ongoing advancements.[13] Data-driven approaches in clinical study, precision medicine, therapeutic innovation, and healthcare policy will be made possible by the digitalization of clinical data. Drug discovery has undergone significant shift in the last decade due to these new analytical methods and computational developments.[14] Recently, there has been a lot of attentiveness in using artificial intelligence approaches to upgrade several phase of the pharmaceutical research channel, including structure-based drug design, de novo molecular modelling and optimization, pre-clinical and clinical development.[15]

To organize the resources required to find effective medications and their therapeutic application, biomedical datasets that include genetic blueprints, visual data, and chemical and pharmacological databases can be combined with analytical techniques, particularly deep learning models.[16] However, by making it possible to analyze vast volumes of data more accurately and efficiently, AI techniques like machine learning (ML) and This procedure could be accelerated and improved using natural language processing.[3] The researchers recently reported on the effective implementation of deep learning (DL) to accurately determine the efficacy of medicinal substances.[17] Using QSAR modeling tools, which have evolved into AI-based QSAR techniques including decision trees, random forest (RF), support vector machines (SVMs), and linear discriminant analysis (LDA) that may be utilized to speed up QSAR analysis, potential therapeutic candidates have been determined.[18] The ability of six AI systems to rank anonymous compounds according to biological activity was compared to traditional approaches, and King et al. found a little statistical difference. The modern tools includes the principle of Computer Aided Drug Development (CADD) during Formulation and Process Optimization in Drug Design.[19,20]

3. Conclusion

The integration of machine learning (ML) and artificial intelligence (AI) is revolutionizing the pharmaceutical research landscape and offering unprecedented opportunities to fundamentally alter the discovery and development of new therapies. Artificial Intelligence and Machine Learning are instigating a paradigm shift in the pharmaceutical industry, encompassing target selection, data analysis, medication development, and the comprehensive optimization of clinical trials. To actualize the benefits of AI in drug development for the enhancement of medical services, it is essential to navigate this promising frontier while balancing ethical considerations with technological advancement. The synergistic integration of human intellect and machinery is propelling advancements toward a future characterized by enhanced precision, personalization, and efficacy in therapeutic interventions.

References

1. Visan AI, Negut I. Integrating artificial intelligence for drug discovery in the context of revolutionizing drug delivery. *Life*. 2024;14(2):1–36. doi: 10.3390/life14020233.
2. Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, et al. Artificial intelligence (AI) applications in drug discovery and drug delivery: Revolutionizing personalized medicine. *Pharmaceutics*. 2024;16(10):1–27. doi: 10.3390/pharmaceutics16101328.
3. Fitria TN. Artificial intelligence (AI) in education: Using AI tools for teaching and learning process. In: Prosiding seminar nasional & call for paper STIE AAS. Surakarta, Jawa Tengah; 2021. p–134–147.
4. Lamberti MJ, Wilkinson M, Donzanti BA, Wohlhieter GE, Parikh S, Wilkins RG, Getz K. A study on the application and use of artificial intelligence to support drug development. *Clin Ther.* 2019; 41(8):1414–26. doi: 10.1016/j.clinthera.2019.05.018.
5. Tiwari PC, Pal R, Chaudhary MJ, Nath R. Artificial intelligence revolutionizing drug development: Exploring opportunities and challenges. *Drug Dev Res*. 2023; 84(8):1652–1663. doi: 10.1002/ddr.22115.
6. Kamila MK, Jasrotia SS. Ethical issues in the development of artificial intelligence: recognizing the risks. *Int. J. Ethics Syst*. 2025;41(1):45–63.
7. Han R, Yoon H, Kim G, Lee H, Lee Y. Revolutionizing medicinal chemistry: the application of artificial intelligence (AI) in early drug discovery. *Pharmaceuticals (Basel)*. 2023; 16(9):1–34. doi: 10.3390/ph16091259.
8. Blanco-Gonzalez A., Cabezon A, Seco-Gonzalez A, Conde-Torres D, Antelo-Riveiro P, Pineiro A, Garcia-Fandino R. The role of AI in drug discovery: challenges, opportunities, and strategies. *Pharmaceuticals(Basel)*. 2023; 16(6):1–11. doi: 10.3390/ph16060891.
9. Vatansever S, Schlessinger A, Wacker D, Kaniskan HÜ, Jin J, Zhou MM, et al. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. *Med Res Rev.* 2021;41(3):1427-73. doi: 10.1002/med.21764.
10. Gupta U, Pranav A, Kohli A, Ghosh S, Singh D. The contribution of artificial intelligence to drug discovery: Current progress and prospects for the future. In: Microbial data intelligence and computational techniques for sustainable computing. 2024. p. 1–23. doi:10.1007/978-981-99-9621-6_1
11. Verma A, Awasthi A. Revolutionizing drug discovery: the role of artificial intelligence and machine learning. *Curr Pharm Des*. 2024;30(11):807–10. doi: 10.2174/0113816128298691240222054120.
12. Zhang K, Yang X, Wang Y, Yu Y, Huang N, Li G, et al. Artificial intelligence in drug development. *Nat Med.* 2025; 31(1), 45–59. doi: 10.1038/s41591-024-03434-4.

13. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. 2021; *Mol Divers.* 25(3), 1315–1360. doi: 10.1007/s11030-021-10217-3.

14. Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, Vale N. Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. *Pharmaceutics*. 2024;16(3):1–39.

15. Selvaraj C, Chandra I, Singh SK. Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries. *Mol Divers*. 2022; 26(3):1893-1913. doi: 10.1007/s11030-021-10326-z.

16. Qureshi R, Irfan M, Gondal TM, Khan S, Wu J, Hadi MU, et al. AI in drug discovery and its clinical relevance. *Heliyon*. 2023;9(7):1–23. doi: 10.1016/j.heliyon.2023.e17575.

17. Blanco-Gonzalez A, Cabezon A, Seco-Gonzalez A, Conde-Torres D, Antelo-Riveiro P, Pineiro A, et al. The role of AI in drug discovery: challenges, opportunities, and strategies. *Pharmaceuticals (Basel)*. 2023;16(6):1–11. doi: 10.3390/ph16060891

18. Parvatikar PP, Patil S, Khaparkhuntikar K, Patil S, Singh PK, Sahana R, et al. Artificial intelligence: Machine learning approach for screening large database and drug discovery. *Antiviral Res.* 2023;220,105740. doi: 10.1016/j.antiviral.2023.105740.

19. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. In: Drug discovery and evaluation: safety and pharmacokinetic assays. 2024 p. 1461–1498. doi:10.1007/978-3-031-35529-5_92

20. Jena BR, Swain SK, Ghose D. Artificial intelligence (A.I), Robotics & Computational Fluid Dynamics. In: Computer aided drug development. 1st Ed. Wood Head Publishing India Pvt. Ltd; 2022. pp. 1–170.

Cite this article: Tripathy S, Swain SK, Jena BR. Application of artificial intelligence in drug development and patient care: An editorial overview. *Indian J Pharma Pharmacol.* 2025;12(3)*:*126-128